TimesSquare Capital Management LLC purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 446,964 shares of the biotechnology company’s stock, valued at approximately $60,984,000. TimesSquare Capital Management LLC owned approximately 0.79% of Repligen at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the company. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen in the third quarter valued at approximately $29,000. Bayforest Capital Ltd bought a new position in Repligen in the 4th quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC acquired a new stake in Repligen during the 4th quarter worth approximately $33,000. Los Angeles Capital Management LLC bought a new stake in Repligen during the 4th quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC grew its holdings in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on RGEN shares. Royal Bank Of Canada assumed coverage on shares of Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. HSBC lowered their target price on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Citigroup upgraded Repligen to a “buy” rating in a research report on Tuesday, July 7th. Finally, Canaccord Genuity Group decreased their price target on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research note on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $166.43.
Insider Activity
In other news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.60% of the stock is owned by corporate insiders.
Repligen Trading Up 1.3%
RGEN opened at $169.04 on Tuesday. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The company has a fifty day moving average of $143.57 and a 200-day moving average of $131.13. The stock has a market cap of $9.54 billion, a PE ratio of 231.56, a price-to-earnings-growth ratio of 3.04 and a beta of 1.03. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26.
Repligen (NASDAQ:RGEN – Get Free Report) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same quarter in the previous year, the business earned $0.26 earnings per share. Repligen’s revenue for the quarter was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts predict that Repligen Corporation will post 2.06 EPS for the current year.
Repligen Company Profile
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Featured Stories
- Five stocks we like better than Repligen
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
